GlobalData on MSN13h
Four regimens fail endpoints simultaneously in HEALEY ALS trial
ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide platform trial.
Opus Genetics, Inc.: Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be pr ...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...
Bionic Sight’s BS01 Gene Therapy Receives RMAT Designation from the FDA
Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP) NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Bionic Sight, Inc., a company ...